Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Analysis of Rubidium PET for CAD Diagnosis
NCT01840696Phase 2Withdrawn
- Sponsor
- Emory University
- Start
- Oct 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regadenoson in coronary artery disease (CAD), sponsored by Emory University. Planned start Oct 2013; status: withdrawn.
02
Drugs
regadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01840696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01840696.